STRS Ohio’s Insight Molecular Diagnostics IMDX Stock Holding History

STRS Ohio’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,515	Closed	-$74K	–	2209
2022 Q1	$74K	Hold	2,515	–	–	﹤0.01%	1896
2021 Q4	$109K	Hold	2,515	–	–	﹤0.01%	1883
2021 Q3	$179K	Buy	2,515 +1,295	+106%	+$119K	﹤0.01%	1803
2021 Q2	$140K	Buy	+1,220	New	+$119K	﹤0.01%	1901
2018 Q2	–	Sell	-230	Closed	-$9K	–	2159
2018 Q1	$9K	Hold	230	–	–	﹤0.01%	1844
2017 Q4	$21K	Hold	230	–	–	﹤0.01%	1817
2017 Q3	$34K	Hold	230	–	–	﹤0.01%	1835
2017 Q2	$23K	Buy	+230	New	+$26.2K	﹤0.01%	1875

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

STRS Ohio's IMDX Position: Q2 2022 in Review

STRS Ohio sold out of Insight Molecular Diagnostics (IMDX) in Q2 2022, closing a stake of 2,515 shares — an estimated $74K sold.

STRS Ohio first reported a position in IMDX in Q2 2017 and held it in 8 quarters. The position peaked at $179K in Q3 2021. 75 funds tracked by Wall St. Rank hold IMDX as of Q2 2022.

STRS Ohio reported no remaining Insight Molecular Diagnostics position as of Q2 2022 after selling out during the quarter.
STRS Ohio sold 2,515 Insight Molecular Diagnostics shares in Q2 2022, an estimated $74K.
STRS Ohio first reported a position in Insight Molecular Diagnostics in Q2 2017 and held it in 8 quarters.
STRS Ohio's Insight Molecular Diagnostics position peaked at $179K in Q3 2021.
75 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2022.

Based on STRS Ohio's 13F filing for Q2 2022, filed 25 Jul 2022.